Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132884 · ClinicalTrials.gov registry record · NA
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
A NA study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02132884 is a NA study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT02132884, a NA study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This randomized clinical trial studies how well genetic sequencing-informed targeted therapy works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of tumor cells that may have less harm to normal cells. Genetic sequencing may help identify these specific types of tumor cells in patients with non-small cell lung cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
- DRUG targeted therapy
- PROCEDURE therapeutic procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132884
The ClinicalTrials.gov registry entry for NCT02132884 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02132884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132884 about?
NCT02132884 is a clinical study titled "Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer". This randomized clinical trial studies how well genetic sequencing-informed targeted therapy works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of tumor cells that...
What is the current status of trial NCT02132884?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2015-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02132884?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER), targeted therapy (DRUG), therapeutic procedure (PROCEDURE).
Who is sponsoring clinical trial NCT02132884?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.